Results 121 to 130 of about 48,917 (272)

Relapsing-remitting multiple sclerosis: advances in disease-modifying therapies [PDF]

open access: yes, 2015
Multiple sclerosis is a demyelinating disease affecting the central nervous system. It is the most prevalent disabling neurological condition among young adults, with onset typically between 20 and 40 years of age. Infiltrating immune cells and microglia
Kay, Kathleen Alexandra
core   +1 more source

Assessment of Small Vessel Density Changes in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalophy (CADASIL) by High‐Resolution Black‐Blood MRI

open access: yesJournal of Magnetic Resonance Imaging, Volume 63, Issue 1, Page 157-168, January 2026.
ABSTRACT Background Direct assessments of cerebral small vessels in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) remain a challenge. Purpose To investigate changes of cerebral small vessels in CADASIL using iso‐0.5 mm black‐blood MRI. Study Type Case control study.
Zidong Yang   +9 more
wiley   +1 more source

A Novel Missense Mutation of the CSF1R Gene Causes Incurable CSF1R-Related Leukoencephalopathy: Case Report and Review of Literature

open access: yesInternational Journal of General Medicine, 2020
Jie Chen,1 Shiying Luo,1 Ning Li,1 Huimin Li,1 Jinming Han,2 Li Ling1 1Department of Neurology, Affiliated Hospital of Hebei University, Baoding, People’s Republic of China; 2Department of Clinical Neuroscience, Karolinska Institutet, Stockholm ...
Chen J, Luo S, Li N, Li H, Han J, Ling L
doaj  

Progressive multifocal leukoencephalopathy: epidemiology and spectrum of predisposing conditions [PDF]

open access: bronze, 2022
Marine Joly   +7 more
openalex   +1 more source

Safety and Effectiveness of Dimethyl Fumarate in Japanese Patients With Multiple Sclerosis: 2‐Year Post‐Marketing Surveillance Data

open access: yesNeurology and Clinical Neuroscience, Volume 14, Issue 1, Page 54-68, January 2026.
ABSTRACT Background Dimethyl fumarate (DMF) is an orally administered disease‐modifying drug used for the treatment of multiple sclerosis (MS) in numerous countries worldwide. Aim An ongoing post‐marketing surveillance (PMS) is assessing the real‐world safety and effectiveness of DMF in Japanese patients with MS.
Hirofumi Ochi   +15 more
wiley   +1 more source

Leukoencephalopathy, a Frequent Complication After High‐Dose Methotrexate in Treatment of Osteosarcoma

open access: yesPediatric Blood &Cancer, Volume 73, Issue 1, January 2026.
ABSTRACT Background Methotrexate‐associated leukoencephalopathy is poorly documented in osteosarcoma. Since 2007, our institution has monitored osteosarcoma patients with sequential magnetic resonance imaging (MRI) and neuropsychological evaluations during treatment and follow‐up.
Sandra Raimbault   +13 more
wiley   +1 more source

COVID-19–associated Diffuse Leukoencephalopathy and Microhemorrhages

open access: green, 2020
Alireza Radmanesh   +8 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy